- Home
- HOWL vs ATNM Comparison
HOWL vs ATNM Comparison
Compare HOWL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- ATNM
- Stock Information
- Founded
- HOWL 2017
- ATNM 2000
- Country
- HOWL United States
- ATNM United States
- Employees
- HOWL N/A
- ATNM N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- ATNM Health Care
- Exchange
- HOWL Nasdaq
- ATNM Nasdaq
- Market Cap
- HOWL 47.1M
- ATNM 55.5M
- IPO Year
- HOWL 2021
- ATNM N/A
- Fundamental
- Price
- HOWL $1.33
- ATNM $1.61
- Analyst Decision
- HOWL Strong Buy
- ATNM Strong Buy
- Analyst Count
- HOWL 5
- ATNM 2
- Target Price
- HOWL $7.20
- ATNM $4.50
- AVG Volume (30 Days)
- HOWL 135.8K
- ATNM 165.6K
- Earning Date
- HOWL 11-06-2025
- ATNM 08-08-2025
- Dividend Yield
- HOWL N/A
- ATNM N/A
- EPS Growth
- HOWL N/A
- ATNM N/A
- EPS
- HOWL N/A
- ATNM N/A
- Revenue
- HOWL N/A
- ATNM N/A
- Revenue This Year
- HOWL N/A
- ATNM N/A
- Revenue Next Year
- HOWL N/A
- ATNM N/A
- P/E Ratio
- HOWL N/A
- ATNM N/A
- Revenue Growth
- HOWL N/A
- ATNM N/A
- 52 Week Low
- HOWL $0.60
- ATNM $1.03
- 52 Week High
- HOWL $4.18
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- HOWL 52.75
- ATNM 44.67
- Support Level
- HOWL $1.29
- ATNM $1.52
- Resistance Level
- HOWL $1.40
- ATNM $1.81
- Average True Range (ATR)
- HOWL 0.07
- ATNM 0.08
- MACD
- HOWL 0.00
- ATNM -0.02
- Stochastic Oscillator
- HOWL 61.90
- ATNM 31.47
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.